Shares of Jazz Pharmaceuticals (JAZZ) rose sharply during the first hour of trade Monday, but settled into a range for the remainder of the day. The stock closed up by 7.17 at $55.29, with volume at a 4 1/2 month high.
Jazz Pharmaceuticals surged past resistance Monday and set a new high for the year. The company reportedly received a positive ruling from its Xyrem patent lawsuit against Roxane Laboratories.
For comments and feedback: editorial@rttnews.com